Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ifebemtinib,Cobimetinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Hyfinity Investments
Deal Size : $15.0 million
Deal Type : Series B Financing
Details : InxMed will use the funds to accelerate ongoing clinical trials of IN10018 (BI 853520) for multiple cancer types in both US and China, including the initiation of pivotal trials, and advance more stroma targeting pipelines into clinics in both US and Chi...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 09, 2022
Lead Product(s) : Ifebemtinib,Cobimetinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Hyfinity Investments
Deal Size : $15.0 million
Deal Type : Series B Financing
Lead Product(s) : T3011,Cobimetinib
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : F. Hoffmann-La Roche
Deal Size : Undisclosed
Deal Type : Agreement
Details : MVR-T3011, ImmVira's proprietary 3-in-1oncolytic herpes simplex virus ("oHSV"), is a novel genetically engineered oHSV which aims to achieve the most favorable profile of attenuated HSV-1 with replication potency in tumor cells.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Undisclosed
April 19, 2022
Lead Product(s) : T3011,Cobimetinib
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : F. Hoffmann-La Roche
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Cobimetinib
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Cobimetinib In Extracranial Arteriovenous Malformations (COBI-AVM Study)
Details : Cobimetinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Arteriovenous Malformations.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 18, 2021
Lead Product(s) : Cobimetinib
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cobimetinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Clinical Research Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cobimetinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Melanoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 25, 2021
Lead Product(s) : Cobimetinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Clinical Research Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vociprotafib,Cobimetinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The ongoing Phase 1b/2 RMC-4630-02 trial is designed to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of RMC-4630 and cobimetinib in adult patients with relapsed/refractory solid tumors that harbor specific genomic mut...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 12, 2020
Lead Product(s) : Vociprotafib,Cobimetinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ifebemtinib,Cobimetinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Ennovation Ventures
Deal Size : $19.0 million
Deal Type : Series A Financing
InxMed Announced the Completion of RMB 130M (~US$ 19M) Series A+ Financing
Details : Funding will support the acceleration of IN10018 clinical program and expand InxMed's portfolio. IN10018 is a potent and selective ATP-competitive focal adhesion kinase small molecule inhibitor.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 03, 2020
Lead Product(s) : Ifebemtinib,Cobimetinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Ennovation Ventures
Deal Size : $19.0 million
Deal Type : Series A Financing
Lead Product(s) : Ifebemtinib,Cobimetinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The combination of KRAS G12C inhibitors and IN10018 induced FAK signaling by KRAS G12C inhibition, serving as one predominant mechanism of drug resistance of KRAS G12C inhibition, and IN10018 significantly decreases the FAK signaling induced by KRAS G12C...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 23, 2020
Lead Product(s) : Ifebemtinib,Cobimetinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cobimetinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations
Details : Cobimetinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 01, 2020
Lead Product(s) : Cobimetinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vociprotafib,Cobimetinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Findings Support Plans to Expand Clinical Evaluation of RMC-4630, the Company’s Investigational SHP2 Inhibitor, to Include Combination with Anti-PD-1 Drug .
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 29, 2020
Lead Product(s) : Vociprotafib,Cobimetinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atezolizumab,Cobimetinib,Vemurafenib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Roche's Tecentriq, on top of targeted drugs, stalls melanoma
Details : In a phase 3 study presented at the American Association for Cancer Research meeting, adding Tecentriq to the targeted melanoma drugs lowered the risk of disease progression.
Product Name : Tecentriq
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 27, 2020
Lead Product(s) : Atezolizumab,Cobimetinib,Vemurafenib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable